Systemic Lupus Erythematosus in a patient with Aquaporin 4-Positive Neuromyelitis Optica Spectrum Disorder
https://orcid.org/0009-0009-0763-881X
Abstract
A 27-year-old female presented with a rapidly progressive demyelinating syndrome with anti aquaporin-4 (AQP4) antibodies, initially diagnosed as neuromyelitis optica spectrum disorder (NMOSD). A comprehensive evaluation, prompted by systemic symptoms including chronic polyarthralgia, bicytopenia, and a history of recurrent pregnancy loss, revealed a concurrent diagnosis of systemic lupus erythematosus (SLE), confirmed by positive antinuclear (ANA) and anti-double-stranded DNA (anti-dsDNA) antibodies. The co-occurrence of AQP4-positive NMOSD and SLE is a rare but well-documented clinical phenomenon that presents a unique diagnostic and therapeutic challenge. This also highlights the need for a thorough rheumatological assessment to identify underlying systemic autoimmune diseases in atypical neurological presentations with extra-neurological signs.
##plugins.themes.bootstrap3.article.details##
Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Demyelinating Disease, Aquaporin 4 Antibodies, Overlap Syndrome, Neuroimmunology
2. Huang TL, Wang JK, Chang PY, et al. Neuromyelitis Optica Spectrum Disorder: From Basic Research to Clinical Perspectives. Int J Mol Sci. 2022 Jul 18;23(14):7908. doi: 10.3390/ijms23147908. PMID: 35887254; PMCID: PMC9323454.
3. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012 Jun;11(6):535-44. doi: 10.1016/S1474-4422(12)70133-3. PMID: 22608667; PMCID: PMC3678971.
4. Moulton VR, Suarez-Fueyo A, Meidan E, et al. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends Mol Med. 2017 Jul;23(7):615-635. doi: 10.1016/j.molmed.2017.05.006. PMID: 28623084; PMCID: PMC5650102.
5. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584. PMID: 20872595.
6. Nashi RA, Shmerling RH. Antinuclear Antibody Testing for the Diagnosis of Systemic Lupus Erythematosus. Med Clin North Am. 2021 Mar;105(2):387-396. doi: 10.1016/j.mcna.2020.10.003. PMID: 33589110.
7. Infantino M, Nagy E, Bizzaro N, et al. Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus. J Transl Autoimmun. 2021 Dec 28;5:100139. doi: 10.1016/j.jtauto.2021.100139. PMID: 35028552; PMCID: PMC8741517.
8. Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol. 2019 Mar;15(3):137-152. doi: 10.1038/s41584-018-0156-8. PMID: 30659245; PMCID: PMC8023338.
9. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010 Jun;6(6):358-67. doi: 10.1038/nrrheum.2010.62. PMID: 20458332.
10. Abou Raya A, Raya SA. Neuromyelitis optica spectrum disorders (NMOSD) and systemic lupus erythematosus (SLE): Dangerous duo. Int J Rheum Dis. 2024 Jan;27(1):e14973. doi: 10.1111/1756-185X.14973PMID: 37975635
11. Krett JD, Filippatou AG, Barreras P, et al. "Lupus Myelitis" Revisited: A Retrospective Single-Center Study of Myelitis Associated With Rheumatologic Disease. Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200329. doi: 10.1212/NXI.0000000000200329. PMID: 39442039; PMCID: PMC11727606
12. Asgari N, Jarius S, Laustrup H, et al. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. Mult Scler. 2018 Mar;24(3):331-339. doi: 10.1177/1352458517699791. PMID: 28326889.
13. Bortoluzzi A, Silvagni E, Furini F, et al. Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence. Clin Exp Rheumatol. 2019 Jan-Feb;37(1):146-155. PMID: 29846158
14. Jarius S, Aktas O, Ayzenberg I, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023 Jul;270(7):3341-3368. doi: 10.1007/s00415-023-11634-0. PMID: 37022481; PMCID: PMC10267280.
15. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. PMID: 37827694
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.